THE HEALTH EQUITY STRATEGIES GROUP, LLC

Lobbying for TRAVERE THERAPEUTICS · Pharmaceutical company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · California · House · $16,000.00 income · posted May 19, 2026

Lobbying activity 4

Health Issues

Rare kidney disease

Medical/Disease Research/Clinical Labs

Rare kidney disease

Medicare/Medicaid

Rare kidney disease

Pharmacy

Rare kidney disease

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.